Diagnosis and treatment of PTP04 related disorders

• US 6,228,641 B1
• Filed: 05/19/1998
• Issued: 05/08/2001
• Est. Priority Date: 05/20/1997
• Status: Expired due to Fees

• Current Assignee: Sugen Incorporated (Pharmacia Corp.)
• Original Assignee: Sugen Incorporated (Pharmacia Corp.)
• Inventors: Jallal, Bahija, Plowman, Gregory D.
• Primary Examiner(s): Caputa, Anthony C.
• Assistant Examiner(s): Holleran, Anne L.
• Application Number:
  US09/081,345
• Time in Patent Office: 1,085 Days
• Field of Search: 536/23.5, 536/23.4, 536/23.2, 536/24.1, 536/24.3, 536/24.31, 435/69.1, 435/70.1, 435/70.3, 435/71.1, 435/320.1, 435/325
• US Class Current: 435/325
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12N 9/1205 Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
• CPC Class Codes: C12N 9/16 acting on ester bonds (3.1)

Abstract

The present invention relates to PTP04 polypetides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for PTP04 related diseases or conditions characterized by an abnormal interaction beteeen a PTP04 polypeptide and a PTP04 binding partner.

Claims

1. An isolated, enriched or purified nucleic acid molecule comprising a nucleotide sequence that

(a) encodes a polypeptide comprising the full length amino acid sequence set forth in SEQ ID NO:

2;

or

(b) is a nucleotide sequence that is completely complementary to the nucleotide sequence of (a).

2. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is isolated, enriched, or purified from a mammal.

3. The nucleic acid molecule of claim 2, wherein said mammal is a human.

4. The nucleic acid molecule of claim 1, further comprising a vector or promoter effective to initiate transcription in a host cell.

5. The nucleic acid molecule of claim 1, further comprising a nucleic acid region that encodes a second polypeptide, wherein said region is fused to said nucleic acid molecule.

6. A recombinant cell comprising the nucleic acid molecule of claim 5.

8. The nucleic acid molecule according to claim 1, wherein said nucleic acid molecule further comprises restriction endonuclease recognition sites at the 5′

end and/or 3′

end of the nucleic acid molecule.

9. The nucleic acid molecule according to claim 4, wherein said vector is pLXSN or pRK5.

10. The nucleic acid molecule according to claim 4, wherein said vector is pGEX.

11. The nucleic acid molecule according to claim 5, wherein said nucleic acid molecule further comprises a foreign nucleic acid sequence which encodes a secretion and/or processing sequence,

so that the nucleic acid molecule encodes a heterologous protein which may be further processed and/or secreted from a cell.

12. The recombinant cell according to claim 6, wherein said nucleic acid molecule further comprises a foreign nucleic acid sequence which encodes a secretion and/or processing sequence,

so that the nucleic acid molecule encodes a heterologous protein which may be further processed and/or secreted from the recombinant cell.

13. The recombinant cell according to claim 6, wherein said recombinant cell is prokaryotic.

14. The recombinant cell according to claim 6, wherein said recombinant cell is eukaryotic.

15. The recombinant cell according to claim 6, wherein said recombinant cell is at least one of a COS cell line, a 293 cell line, a PA 317 cell line, an NIH-3T3 cell line or a BALB/3T3 cell line.

7. An isolated, enriched or purified nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:

1.